Key Points
- EVP Paul Mahon sold 8,300 United Therapeutics shares on Feb. 5 at an average of $483.25 for about $4.01M, cutting his holding by 18.41% to 36,781 shares (disclosed in an SEC filing).
- United Therapeutics trades around $479 with a market cap of $20.62B and a PE of 18.15; analysts give a consensus "Moderate Buy" rating with an average price target of $509.50 (notable targets include UBS $645 and Jefferies $575).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $483.25, for a total value of $4,010,975.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $17,774,418.25. This trade represents a 18.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Down 0.8%
NASDAQ:UTHR opened at $478.93 on Friday. The firm has a market capitalization of $20.62 billion, a PE ratio of 18.15, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The stock's 50-day simple moving average is $486.76 and its 200 day simple moving average is $425.24. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.
Analysts Set New Price Targets
UTHR has been the topic of several recent research reports. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 30th. UBS Group upped their target price on United Therapeutics from $600.00 to $645.00 and gave the company a "buy" rating in a report on Tuesday, January 6th. Jefferies Financial Group restated a "buy" rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a research report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $509.50.
Read Our Latest Research Report on United Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Torren Management LLC acquired a new position in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
